These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 26103979)

  • 1. Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).
    Fautrel B; Pham T; Alfaiate T; Gandjbakhch F; Foltz V; Morel J; Dernis E; Gaudin P; Brocq O; Solau-Gervais E; Berthelot JM; Balblanc JC; Mariette X; Tubach F
    Ann Rheum Dis; 2016 Jan; 75(1):59-67. PubMed ID: 26103979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
    van Herwaarden N; van der Maas A; Minten MJ; van den Hoogen FH; Kievit W; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; den Broeder AA
    BMJ; 2015 Apr; 350():h1389. PubMed ID: 25858265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.
    Bouman CA; van Herwaarden N; van den Hoogen FH; Fransen J; van Vollenhoven RF; Bijlsma JW; Maas AV; den Broeder AA
    Ann Rheum Dis; 2017 Oct; 76(10):1716-1722. PubMed ID: 28606961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapering and discontinuation of TNF-α blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission.
    Alivernini S; Peluso G; Fedele AL; Tolusso B; Gremese E; Ferraccioli G
    Arthritis Res Ther; 2016 Feb; 18():39. PubMed ID: 26842890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
    Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
    Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial.
    Sigaux J; Bailly F; Hajage D; Mariette X; Morel J; Gandjbakhch F; Foltz V; Gossec L; Tubach F; Fautrel B
    RMD Open; 2017; 3(2):e000474. PubMed ID: 28955495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug outcome survey to evaluate anti-TNF treatment in rheumatoid arthritis: an Italian observational study (the DOSE study).
    Anecchino C; Fanizza C; Marino V; Romero M;
    Clin Exp Rheumatol; 2015; 33(6):779-87. PubMed ID: 26575614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Im
    Emery P; Burmester GR; Naredo E; Zhou Y; Hojnik M; Conaghan PG
    BMJ Open; 2018 Feb; 8(2):e019007. PubMed ID: 29490959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
    Kievit W; van Herwaarden N; van den Hoogen FH; van Vollenhoven RF; Bijlsma JW; van den Bemt BJ; van der Maas A; den Broeder AA
    Ann Rheum Dis; 2016 Nov; 75(11):1939-1944. PubMed ID: 26764260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?
    Ibrahim F; Lorente-Cánovas B; Doré CJ; Bosworth A; Ma MH; Galloway JB; Cope AP; Pande I; Walker D; Scott DL
    Rheumatology (Oxford); 2017 Nov; 56(11):2004-2014. PubMed ID: 28968858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC; Pope JE; Thorne JC; Poulin-Costello M; Phan-Chronis K; Vieira A; Haraoui B;
    Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.
    Haschka J; Englbrecht M; Hueber AJ; Manger B; Kleyer A; Reiser M; Finzel S; Tony HP; Kleinert S; Feuchtenberger M; Fleck M; Manger K; Ochs W; Schmitt-Haendle M; Wendler J; Schuch F; Ronneberger M; Lorenz HM; Nuesslein H; Alten R; Demary W; Henes J; Schett G; Rech J
    Ann Rheum Dis; 2016 Jan; 75(1):45-51. PubMed ID: 25660991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ability to predict rheumatoid arthritis relapse after tumour necrosis factor inhibitor tapering by the Multi-Biomarker Disease Activity Score: a post-hoc analysis of the STRASS trial.
    Moysidou GS; Marotte H; Kossi S; Tubach F; Hajage D; Fautrel B
    Clin Exp Rheumatol; 2023 Sep; 41(9):1831-1837. PubMed ID: 37497730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
    Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
    Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
    Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [TNF inhibitors].
    Kameda H
    Nihon Rinsho; 2016 Jun; 74(6):957-62. PubMed ID: 27311185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
    van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
    Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.